Active Ingredient: Tisagenlecleucel
Tisagenlecleucel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
60,000,000 - 600,000,000 [CCID_50]
From 60,000,000 To 600,000,000 [CCID_50] once every day
Tisagenlecleucel must be administered in a qualified treatment centre. Therapy should be initiated under the direction of and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with tisagenlecleucel. A minimum of four doses of tocilizumab for use in the event of cytokine release syndrome and emergency equipment must be available prior to infusion.
Tisagenlecleucel is intended for autologous use only. Manufacture and release of tisagenlecleucel usually takes about 3-4 weeks.
Dosage in adult DLBCL patients:
Lymphodepleting chemotherapy is recommended to be administered before tisagenlecleucel infusion unless the white blood cell (WBC) count within one week prior to infusion is ≤1,000 cells/μL. Tisagenlecleucel is recommended to be infused 2 to 14 days after completion of the lymphodepleting chemotherapy. The availability of tisagenlecleucel must be confirmed prior to starting the lymphodepleting regimen. If there is a delay of more than 4 weeks between completing lymphodepleting chemotherapy and the infusion and the WBC count is >1,000 cells/μL, then the patient should be re-treated with lymphodepleting chemotherapy prior to receiving tisagenlecleucel.
The recommended lymphodepleting chemotherapy regimen is:
To minimise potential acute infusion reactions, it is recommended that patients be pre-medicated with paracetamol and diphenhydramine or another H1 antihistamine within approximately 30 to 60 minutes prior to tisagenlecleucel infusion. Corticosteroids should not be used at any time except in the case of a life-threatening emergency.
Tisagenlecleucel treatment should be delayed in some patient groups at risk.
Patients should be monitored daily for the first 10 days following infusion for signs and symptoms of potential cytokine release syndrome, neurological events and other toxicities. Physicians should consider hospitalisation for the first 10 days post infusion or at the first signs/symptoms of cytokine release syndrome and/or neurological events.
After the first 10 days following the infusion, the patient should be monitored at the physician’s discretion.
Patients should be instructed to remain within proximity of a qualified clinical facility for at least 4 weeks following infusion.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
